Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.

Oncotarget · 2017 · PMC5355234 · PMID 28051996

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Comparison of blood and tumor clearance of 123 I-scFvD2B with data obtained previously with 131 I-scFvD2B [ 16 ] suggested an improvement due to a clear trend toward a shorter circulatory half-life and a longer retention in PSMA-positive tumors.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.